Developer docs
API playgroundTry for free, no card

Search company profiles

Metrion Biosciences

Full company profile

uuid0002nfl

Namestring
Metrion Biosciences
Legal namestring
Metrion Biosciences Limited
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Metrion Biosciences is a specialist preclinical Contract Research Organization (CRO) founded in 2015 and headquartered at the Granta Park bio-cluster in Cambridge, UK. The company delivers ion channel electrophysiology drug discovery services to pharmaceutical and biotechnology clients globally, with explicit operating geographies across Europe, North America, and Asia. Its service portfolio spans four integrated pillars: ion channel screening (high-throughput screening, assay development, cell line generation), cardiac safety screening (GLP hERG testing, CiPA-compliant profiling, clinically translatable hiPSC-derived cardiomyocyte assays, chronic cardiotoxicity screening), neuroscience (brain slice electrophysiology, native neuronal assays, central neuronal firing, pain research targeting NaV1.7/1.8/1.9 and K2P channels), and integrated drug discovery support.

The technology platform is built around automated patch clamp electrophysiology using Sophion Qube-384, QPatch II-48, and QPatch-48 instruments, supplemented by manual patch clamp, Multi-Electrode Array, FLIPR-Penta, impedance, and FlexStation platforms. Metrion has developed proprietary validated cell lines — most notably NaV1.9 in human and rat CHO backgrounds — and bespoke assays including the CiPA Milnes hERG kinetic assay and alternative seal enhancer methodologies. Its April 2025 NaV1.9 high-throughput screening launch completes a full pain-related sodium channel suite. Customers include Jazz Pharmaceuticals, Latigo Biotherapeutics, and Aligos Therapeutics, with testimonials emphasizing scientific intellectual contribution, data format integration, and reproducibility.

The business model is fee-for-service / professional services: standard and bespoke research projects quoted per scope, billed on multi-year contracts with pharma and biotech clients, plus a smaller collaboration-based revenue stream. Distribution is direct enterprise field sales, supported by a recently expanded commercial organization. Metrion is venture-backed, having raised approximately £3.7m in December 2023 led by Maven Capital Partners alongside Gresham House Ventures (which previously led a £2.7m round in 2021), with board representation from both investors. The company has scaled to 42 employees as of March 2024 (a 55% increase since 2022), reported FY2022 turnover of £5.3m (up from £1.5m in FY2018), and was listed in The Sunday Times 100 Tech in January 2025 alongside its 10-year anniversary.

Short descriptiontext

Metrion Biosciences is a specialist preclinical CRO providing ion channel electrophysiology, cardiac safety (GLP hERG, CiPA), and neuroscience screening services to pharmaceutical and biotechnology companies globally, operating from Cambridge, UK.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ion channel screening, cardiac safety testing, preclinical drug discovery, electrophysiology services, neuroscience CRO
Industry2 codes
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Drug Discovery Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services (Fee-for-Service)
TypeProfessional Services
Description

Metrion operates as a specialist preclinical contract research organization (CRO) providing high-quality ion channel electrophysiology screening services on a fee-for-service or collaboration basis. Services include ion channel screening, cardiac safety screening (GLP hERG testing, CiPA profiling), neuroscience assays, and integrated drug discovery. Revenue is generated through project-based fees for screening assays, assay development, and characterization services tailored to customer medicinal chemistry optimization programs.

metrionbiosciences.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Custom assay services quoted per project
ModelOtherBilling cadenceMulti-year contract
Notes

Services are available via standard or bespoke research projects; pricing is quote-based and tailored to each customer's requirements. No public pricing tiers listed.

metrionbiosciences.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Metrion Biosciences is a specialist preclinical Contract Research Organization (CRO) providing ion channel, cardiac safety, and neuroscience drug discovery services on a fee-for-service basis to pharmaceutical and biotechnology companies. Services include high-throughput ion channel screening, GLP hERG and CiPA-compliant cardiac safety profiling, brain slice and native neuronal electrophysiology, pain research assays, and integrated drug discovery support. The company operates automated patch clamp platforms (Sophion Qube-384, QPatch II-48, QPatch-48) alongside FLIPR-Penta, manual patch clamp, multi-electrode array, and impedance systems from its Cambridge laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Metrion's NaV1.9 assay using TC-N 1752 showed concentration-dependent inhibition with IC50 of 0.45 µM, demonstrating robust pharmacological characterization capability.
+2 more records
Product overview1 text field

Metrion Biosciences is a specialist preclinical Contract Research Organization (CRO) providing ion channel drug discovery services. The offering consists of four integrated service pillars: Ion Channel Screening Services (including high-throughput screening and cell line generation), Cardiac Safety Screening Services (including GLP hERG testing, hiPSC cardiomyocyte assays, and CiPA-compliant screening), Neuroscience Services (including brain slice electrophysiology, native neuronal assays, and pain research), and Integrated Drug Discovery Services. The Company operates from Cambridge, UK using automated patch clamp platforms (Qube-384, QPatch) and provides expert interpretation and strategic recommendations. In April 2025, the Company launched a NaV1.9 high-throughput screening assay to strengthen its pain drug discovery portfolio.

Product and service5 records
1Ion Channel Screening Services
CategoryIon Channel Screening
Description

Specialist ion channel screening services including high-throughput screening, assay development, and cell line generation for drug discovery programs targeting voltage-gated and ligand-gated ion channels. Delivered to pharmaceutical and biotechnology customers using automated patch clamp platforms.

2Cardiac Safety Screening Services
CategoryCardiac Safety Screening
Description

Comprehensive cardiac safety profiling including GLP hERG testing, hERG screening assays, CiPA-compliant screening, and clinically translatable hiPSC cardiomyocyte assays for proarrhythmia risk assessment under ICH S7A/S7B and CiPA regulatory frameworks.

3Neuroscience Services
CategoryNeuroscience Drug Discovery
Description

Neuroscience drug discovery services including brain slice electrophysiology, native neuronal ion channel assays, central neuronal firing analysis, pain research, and translational assays for CNS drug discovery.

4Integrated Drug Discovery
CategoryIntegrated Drug Discovery
Description

Comprehensive integrated drug discovery services combining ion channel expertise, electrophysiology platforms, and strategic consulting to support hit-to-lead and lead optimization programs for pharmaceutical and biotech customers.

5NaV1.9 High-Throughput Screening Assay
CategoryPain Research Ion Channel Assay
Description

Validated high-throughput screening assay for NaV1.9 sodium channel targeting chronic pain signaling. Uses stable CHO cell lines with human and rat clones on Qube 384 and QPatch 48 platforms for reproducible, decision-ready data in pain drug discovery programs.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration on automated patch clamp technology. Metrion utilizes Sophion QPatch 48, QPatch II-48, and Qube 384 platforms for ion channel screening assays. Joint development of alternative seal enhancers for Qube 384 to overcome limitations of CaF2.

Strategic tierCoreTypeTechnology or Integration
Description

Product integration partnership for Qube 384 automated patch clamp platform. Studies performed in parallel at Sophion and Metrion for CHO-KV1.3 current clamp characterization.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration to determine whether alternative insoluble salts can act as seal enhancers on Qube 384 platform, addressing limitations of CaF2 which can interfere with G-protein modulation of ion channels and Ca2+-activated ion channels.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Strategic alliance for hit identification against ion channel targets. Domainex contributes experience in hit identification while Metrion provides expertise in ion channel screening and pharmacology. Collaboration includes TRPA1 antagonist case study.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration using Targeted Venom Discovery Array (T-VDA) library for high-throughput screening of venom fractions to identify novel TREK-1 modulators using automated patch clamp electrophysiology.

6Universities of Kent and Greenwich
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration with Emma Veale and Alistair Mathie on potassium channel research. Published paper on NS5806 activation of TREK-1 and TREK-2 channels in Pharmacology Research & Perspectives.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Industry Fellowship sponsored by Metrion for Dr Emma Veale's investigation of K2P (two-pore domain potassium) channels as potential drug targets, particularly in pain research. Fellowship spans four years.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

Collaboration utilizing Metrion's high-throughput VOLTA assay with human iPSC-derived cardiomyocytes for cardiac safety assessment. Jazz contributed poster data on predicting drug-induced changes in ECG parameters during drug discovery.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global mega-CRO offering an integrated cardiac safety and preclinical safety portfolio following its acquisition of ChanTest (the former employer of Metrion's CCO). Directly competes with Metrion on hERG/CiPA and ion-channel services but at much larger scale and as part of a broader service catalogue.

TypeBroad incumbent
Description

Discovery and preclinical CRO arm of Eurofins, offering ion-channel and cardiac safety profiling (including via the former Icagen business). Comparable to Metrion on screening services but with substantially greater scale, geographic reach and bundling with adjacent ADME/tox offerings.

TypeBroad incumbent
Description

Large integrated CRO/platform company providing preclinical safety and discovery services (including via Cyprotex). Overlaps with Metrion on cardiac safety and ion-channel pharmacology, but Evotec operates an end-to-end discovery-to-manufacturing model that competes for the same big-pharma outsourcing wallet.

TypeDirect peer
Description

Germany-based specialist preclinical CRO with a deep ion-channel electrophysiology offering (QPatch-based services, cardiac safety profiling). Closest direct competitor to Metrion on technology, customer base and service scope.

TypeDirect peer
Description

US-based specialty CRO focused on human tissue-based cardiac safety and pain electrophysiology. Direct overlap with Metrion's cardiac safety and neuroscience service lines; also a former employer of Metrion's CCO, indicating close competitive and talent overlap.

TypeDirect peer
Description

Specialist ion-channel drug-discovery CRO (acquired by Eurofins) providing screening, assay development and cardiac safety services. Closely comparable to Metrion's core ion-channel offering and frequently bid against on pharma preclinical programmes.

TypeDirect peer
Description

UK-based integrated drug-discovery CRO with ion-channel screening and medicinal chemistry capabilities. Both strategic partner (TRPA1 hit ID alliance) and competitor for hit-to-lead ion-channel programmes, particularly within the UK biotech ecosystem.

TypeOthers
Description

Automated patch clamp instrument vendor (QPatch, Qube) and R&D collaborator. Core platform supplier to Metrion (joint seal-enhancer work) and adjacent services competitor via its own CRO customers.

TypeOthers
Description

Provider of automated patch clamp and ion-channel screening instruments (SyncroPatch, Port-a-Patch) and collaborator on ASIC1a assay development. Key enabling platform for ion-channel CROs and adjacent competitor for screening services.

TypeDirect peer
Description

Stem-cell-focused CRO offering iPSC-derived cardiomyocyte safety assays and CNS disease models. Comparable to Metrion on hiPSC cardiomyocyte cardiac safety and neuroscience translational services, competing for similar translational-stage customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Metrion Biosciences

Preclinical Drug Discovery Servicesmetrionbiosciences.com

Metrion Biosciences is a specialist preclinical CRO providing ion channel electrophysiology, cardiac safety (GLP hERG, CiPA), and neuroscience screening services to pharmaceutical and biotechnology companies globally, operating from Cambridge, UK.

What Metrion Biosciences does

Metrion Biosciences is a specialist preclinical Contract Research Organization (CRO) founded in 2015 and headquartered at the Granta Park bio-cluster in Cambridge, UK. The company delivers ion channel electrophysiology drug discovery services to pharmaceutical and biotechnology clients globally, with explicit operating geographies across Europe, North America, and Asia. Its service portfolio spans four integrated pillars: ion channel screening (high-throughput screening, assay development, cell line generation), cardiac safety screening (GLP hERG testing, CiPA-compliant profiling, clinically translatable hiPSC-derived cardiomyocyte assays, chronic cardiotoxicity screening), neuroscience (brain slice electrophysiology, native neuronal assays, central neuronal firing, pain research targeting NaV1.7/1.8/1.9 and K2P channels), and integrated drug discovery support.

The technology platform is built around automated patch clamp electrophysiology using Sophion Qube-384, QPatch II-48, and QPatch-48 instruments, supplemented by manual patch clamp, Multi-Electrode Array, FLIPR-Penta, impedance, and FlexStation platforms. Metrion has developed proprietary validated cell lines — most notably NaV1.9 in human and rat CHO backgrounds — and bespoke assays including the CiPA Milnes hERG kinetic assay and alternative seal enhancer methodologies. Its April 2025 NaV1.9 high-throughput screening launch completes a full pain-related sodium channel suite. Customers include Jazz Pharmaceuticals, Latigo Biotherapeutics, and Aligos Therapeutics, with testimonials emphasizing scientific intellectual contribution, data format integration, and reproducibility.

The business model is fee-for-service / professional services: standard and bespoke research projects quoted per scope, billed on multi-year contracts with pharma and biotech clients, plus a smaller collaboration-based revenue stream. Distribution is direct enterprise field sales, supported by a recently expanded commercial organization. Metrion is venture-backed, having raised approximately £3.7m in December 2023 led by Maven Capital Partners alongside Gresham House Ventures (which previously led a £2.7m round in 2021), with board representation from both investors. The company has scaled to 42 employees as of March 2024 (a 55% increase since 2022), reported FY2022 turnover of £5.3m (up from £1.5m in FY2018), and was listed in The Sunday Times 100 Tech in January 2025 alongside its 10-year anniversary.

Metrion Biosciences firmographics

Firmographics
Name
Metrion Biosciences
Legal name
Metrion Biosciences Limited
Website
https://metrionbiosciences.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Metrion Biosciences is a specialist preclinical CRO providing ion channel electrophysiology, cardiac safety (GLP hERG, CiPA), and neuroscience screening services to pharmaceutical and biotechnology companies globally, operating from Cambridge, UK.
Ownership category
akta.pro rank

Metrion Biosciences industry classification

Industry
Product category
Preclinical Drug Discovery Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)

Keywords

  • Ion channel screening
  • Cardiac safety testing
  • Preclinical drug discovery
  • Electrophysiology services
  • Neuroscience CRO

Where Metrion Biosciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Metrion Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Research Services (Fee-for-Service): Metrion operates as a specialist preclinical contract research organization (CRO) providing high-quality ion channel electrophysiology screening services on a fee-for-service or collaboration basis. Services include ion channel screening, cardiac safety screening (GLP hERG testing, CiPA profiling), neuroscience assays, and integrated drug discovery. Revenue is generated through project-based fees for screening assays, assay development, and characterization services tailored to customer medicinal chemistry optimization programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom assay services quoted per project

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Metrion Biosciences product offering

Product offering

Core offering

Metrion Biosciences is a specialist preclinical Contract Research Organization (CRO) providing ion channel, cardiac safety, and neuroscience drug discovery services on a fee-for-service basis to pharmaceutical and biotechnology companies. Services include high-throughput ion channel screening, GLP hERG and CiPA-compliant cardiac safety profiling, brain slice and native neuronal electrophysiology, pain research assays, and integrated drug discovery support. The company operates automated patch clamp platforms (Sophion Qube-384, QPatch II-48, QPatch-48) alongside FLIPR-Penta, manual patch clamp, multi-electrode array, and impedance systems from its Cambridge laboratories.

Product overview

Metrion Biosciences is a specialist preclinical Contract Research Organization (CRO) providing ion channel drug discovery services. The offering consists of four integrated service pillars: Ion Channel Screening Services (including high-throughput screening and cell line generation), Cardiac Safety Screening Services (including GLP hERG testing, hiPSC cardiomyocyte assays, and CiPA-compliant screening), Neuroscience Services (including brain slice electrophysiology, native neuronal assays, and pain research), and Integrated Drug Discovery Services. The Company operates from Cambridge, UK using automated patch clamp platforms (Qube-384, QPatch) and provides expert interpretation and strategic recommendations. In April 2025, the Company launched a NaV1.9 high-throughput screening assay to strengthen its pain drug discovery portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ion Channel Screening Services Specialist ion channel screening services including high-throughput screening, assay development, and cell line generation for drug discovery programs targeting voltage-gated and ligand-gated ion channels. Delivered to pharmaceutical and biotechnology customers using automated patch clamp platforms.
  • Cardiac Safety Screening Services Comprehensive cardiac safety profiling including GLP hERG testing, hERG screening assays, CiPA-compliant screening, and clinically translatable hiPSC cardiomyocyte assays for proarrhythmia risk assessment under ICH S7A/S7B and CiPA regulatory frameworks.
  • Neuroscience Services Neuroscience drug discovery services including brain slice electrophysiology, native neuronal ion channel assays, central neuronal firing analysis, pain research, and translational assays for CNS drug discovery.
  • Integrated Drug Discovery Comprehensive integrated drug discovery services combining ion channel expertise, electrophysiology platforms, and strategic consulting to support hit-to-lead and lead optimization programs for pharmaceutical and biotech customers.
  • NaV1.9 High-Throughput Screening Assay Validated high-throughput screening assay for NaV1.9 sodium channel targeting chronic pain signaling. Uses stable CHO cell lines with human and rat clones on Qube 384 and QPatch 48 platforms for reproducible, decision-ready data in pain drug discovery programs.

Quantifiable outcome

  • Metrion's NaV1.9 assay using TC-N 1752 showed concentration-dependent inhibition with IC50 of 0.45 µM, demonstrating robust pharmacological characterization capability.
  • +2 more outcomes

Companies that use Metrion Biosciences

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Metrion Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Metrion Biosciences partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core, strategic and minor.

  • Sophion BiosciencecoreTechnology or IntegrationCollaboration on automated patch clamp technology. Metrion utilizes Sophion QPatch 48, QPatch II-48, and Qube 384 platforms for ion channel screening assays. Joint development of alternative seal enhancers for Qube 384 to overcome limitations of CaF2.
  • Sophion BiosciencecoreTechnology or IntegrationProduct integration partnership for Qube 384 automated patch clamp platform. Studies performed in parallel at Sophion and Metrion for CHO-KV1.3 current clamp characterization.
  • Sophion BiosciencecoreTechnology or IntegrationCollaboration to determine whether alternative insoluble salts can act as seal enhancers on Qube 384 platform, addressing limitations of CaF2 which can interfere with G-protein modulation of ion channels and Ca2+-activated ion channels.
  • DomainexstrategicStrategic or Co-development PartnerStrategic alliance for hit identification against ion channel targets. Domainex contributes experience in hit identification while Metrion provides expertise in ion channel screening and pharmacology. Collaboration includes TRPA1 antagonist case study.
  • VenomtechminorStrategic or Co-development PartnerCollaboration using Targeted Venom Discovery Array (T-VDA) library for high-throughput screening of venom fractions to identify novel TREK-1 modulators using automated patch clamp electrophysiology.
  • Universities of Kent and GreenwichminorStrategic or Co-development PartnerAcademic collaboration with Emma Veale and Alistair Mathie on potassium channel research. Published paper on NS5806 activation of TREK-1 and TREK-2 channels in Pharmacology Research & Perspectives.
  • University of Kent - Medway School of PharmacologyminorStrategic or Co-development PartnerIndustry Fellowship sponsored by Metrion for Dr Emma Veale's investigation of K2P (two-pore domain potassium) channels as potential drug targets, particularly in pain research. Fellowship spans four years.
  • Jazz PharmaceuticalsstrategicStrategic or Co-development PartnerCollaboration utilizing Metrion's high-throughput VOLTA assay with human iPSC-derived cardiomyocytes for cardiac safety assessment. Jazz contributed poster data on predicting drug-induced changes in ECG parameters during drug discovery.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Metrion Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Global mega-CRO offering an integrated cardiac safety and preclinical safety portfolio following its acquisition of ChanTest (the former employer of Metrion's CCO). Directly competes with Metrion on hERG/CiPA and ion-channel services but at much larger scale and as part of a broader service catalogue.
  • Eurofins Discovery: Discovery and preclinical CRO arm of Eurofins, offering ion-channel and cardiac safety profiling (including via the former Icagen business). Comparable to Metrion on screening services but with substantially greater scale, geographic reach and bundling with adjacent ADME/tox offerings.
  • Evotec: Large integrated CRO/platform company providing preclinical safety and discovery services (including via Cyprotex). Overlaps with Metrion on cardiac safety and ion-channel pharmacology, but Evotec operates an end-to-end discovery-to-manufacturing model that competes for the same big-pharma outsourcing wallet.

Direct peers

  • NMI TT Pharmaservices: Germany-based specialist preclinical CRO with a deep ion-channel electrophysiology offering (QPatch-based services, cardiac safety profiling). Closest direct competitor to Metrion on technology, customer base and service scope.
  • AnaBios: US-based specialty CRO focused on human tissue-based cardiac safety and pain electrophysiology. Direct overlap with Metrion's cardiac safety and neuroscience service lines; also a former employer of Metrion's CCO, indicating close competitive and talent overlap.
  • Icagen: Specialist ion-channel drug-discovery CRO (acquired by Eurofins) providing screening, assay development and cardiac safety services. Closely comparable to Metrion's core ion-channel offering and frequently bid against on pharma preclinical programmes.
  • Domainex: UK-based integrated drug-discovery CRO with ion-channel screening and medicinal chemistry capabilities. Both strategic partner (TRPA1 hit ID alliance) and competitor for hit-to-lead ion-channel programmes, particularly within the UK biotech ecosystem.
  • Reprocell: Stem-cell-focused CRO offering iPSC-derived cardiomyocyte safety assays and CNS disease models. Comparable to Metrion on hiPSC cardiomyocyte cardiac safety and neuroscience translational services, competing for similar translational-stage customers.

Others

  • Sophion Bioscience: Automated patch clamp instrument vendor (QPatch, Qube) and R&D collaborator. Core platform supplier to Metrion (joint seal-enhancer work) and adjacent services competitor via its own CRO customers.
  • Nanion Technologies: Provider of automated patch clamp and ion-channel screening instruments (SyncroPatch, Port-a-Patch) and collaborator on ASIC1a assay development. Key enabling platform for ion-channel CROs and adjacent competitor for screening services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Metrion Biosciences social profiles

Digital presence

Metrion Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Metrion Biosciences leadership team

Management profile

Number of profiles

Profiles10 records

Metrion Biosciences funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Metrion Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metrion Biosciences

What does Metrion Biosciences do?

Metrion Biosciences is a specialist preclinical Contract Research Organization (CRO) providing ion channel, cardiac safety, and neuroscience drug discovery services on a fee-for-service basis to pharmaceutical and biotechnology companies. Services include high-throughput ion channel screening, GLP hERG and CiPA-compliant cardiac safety profiling, brain slice and native neuronal electrophysiology, pain research assays, and integrated drug discovery support. The company operates automated patch clamp platforms (Sophion Qube-384, QPatch II-48, QPatch-48) alongside FLIPR-Penta, manual patch clamp, multi-electrode array, and impedance systems from its Cambridge laboratories.

Is Metrion Biosciences a public or private company?

Metrion Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Metrion Biosciences founded?

Metrion Biosciences was founded in 2015. It employs 11 to 50 people.

Where is Metrion Biosciences based?

Metrion Biosciences is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Metrion Biosciences make money?

One revenue line is on record: contract Research Services (Fee-for-Service).

Who are Metrion Biosciences's main competitors?

Broad incumbents on record are Charles River Laboratories, Eurofins Discovery and Evotec. Direct peers are NMI TT Pharmaservices, AnaBios, Icagen, Domainex and Reprocell. Others are Sophion Bioscience and Nanion Technologies.

Does Metrion Biosciences have an API?

No public API is recorded for Metrion Biosciences.

What industry is Metrion Biosciences in?

Metrion Biosciences's product category is Preclinical Drug Discovery Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 54171 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireHERG Screening Market Analysis Report 2026: $3.21 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035FThe HERG screening market is projected to grow from $1.84 billion in 2025 to $3.21 billion by 2030, driven by increased cardiac-related drug withdrawals, advancements in AI-driven predictive toxicology, and organ-on-chip technologies. Key growth factors include the rising prevalence of heart disorders and an aging global population, with North America holding the largest market share in 2025 while Asia-Pacific is expected to see the fastest growth. Industry leaders such as Metrion Biosciences Ltd., Eurofins-Cerep SA, AstraZeneca, and Merck KGaA are among the prominent players offering HERG screening services, though the market faces challenges including tariffs that have disrupted supply chains.News-MedicalMetrion Biosciences appoints Dr Chris Mathes as Chief Commercial OfficerMetrion Biosciences appointed Dr Chris Mathes as Chief Commercial Officer. He brings over 25 years of experience in the preclinical CRO space and will lead global business development and marketing. The appointment follows the company's £3.7M equity financing in December 2023.FinSMEsMetrion Biosciences Raises £3.7M in New Equity FundingMetrion Biosciences raised £3.7M in equity funding led by Maven Capital Partners with Gresham House Ventures. The company will use the funds to expand its Cambridge laboratories, invest in equipment, and enhance global marketing. It also appointed Dr David Milroy and Steve Carle to the board.BioSpaceMetrion Biosciences Closes £3.7m New Equity FinancingMetrion Biosciences Limited has secured £3.5 million in new equity financing to expand its laboratories in Cambridge, UK, and enhance its scientific and commercial capabilities. The funding includes £2.5 million from lead investor Maven Capital Partners and £1 million from Gresham House Ventures. Board changes were also announced, with new appointments and retirements among directors.Business Wire BlogMetrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US operationsMetrion Biosciences appointed Dr Steve Jenkinson as Vice President of Drug Discovery and Safety Assessment to support its US operations. He brings over 25 years of drug discovery leadership, including roles at Pfizer and GSK. The appointment aims to strengthen Metrion's ion channel contract research and safety pharmacology services for US clients.BioSpaceMetrion Biosciences Appoints Dr Benedetta Montagnini as Head of European Business DevelopmentMetrion Biosciences appointed Dr Benedetta Montagnini as Head of European Business Development, based in Rome. She will support existing clients and lead new business opportunities in ion channel drug discovery. The appointment follows the creation of a Client Services team and expansion of operations.BioSpaceMetrion Biosciences Appoints Dr Rory Curtis as Vice President US Commercial OperationsMetrion Biosciences appointed Dr Rory Curtis as Vice President US Commercial Operations, effective immediately. He will lead business development in the US, building on his 25-year drug discovery career at companies like Regeneron and Millennium. The appointment supports Metrion's expansion in the North American ion channel services market.Science Laboratory Equipment News From Labmate OnlineStrategic move sets new growth trajectoryMetrion Biosciences moved into new 12,000 sq ft labs at Granta Park Cambridge, doubling its lab space. The company plans a 384-well automated electrophysiology system operational in Q4 2021 and will hire in 2022. It also aims to offer GLP hERG screening from Q1 2022.BioSpaceMetrion Biosciences Expands Into New Headquarters to Support Continued GrowthMetrion Biosciences moved to a 12,000 sq ft headquarters in Granta Park, Cambridge, UK, more than doubling its laboratory space. The facility supports GLP cardiac safety services, expanded cell biology, and 384-well automated electrophysiology. The company plans to focus on the USA in 2022 and is actively recruiting.BioSpaceMetrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business DevelopmentMetrion Biosciences appointed Nick Foster as Chief Commercial Officer and Head of Global Business Development to support international growth. The appointment follows a £2.7m equity investment led by Gresham House Ventures and aims to expand the company's customer base in the USA, EU, and Japan.